Related Experiment Video
Updated: Jun 30, 2025
03:13
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
2.2K
Refractory Ischemic Priapism Following Hemodialysis
Abdalhai Alshoubi1, Farris Al-Qawasmi2
1Anesthesiology and Critical Care, OSF Saint Francis Medical Center, Peoria, USA.
Cureus
|March 18, 2024
Summary
This case study details a rare instance of prolonged, painful penile erection (priapism) in a hemodialysis patient. Erythropoietin and heparin during dialysis may contribute to this serious urological emergency.
Area of Science:
- Urology
- Nephrology
- Hematology
Background:
- Priapism is a rare urological emergency with varied causes.
- Hemodialysis patients, particularly those with diabetes and hypertension, face unique health challenges.
Observation:
- A 57-year-old male with end-stage renal disease on hemodialysis developed refractory ischemic priapism.
- Standard treatments failed, requiring surgical intervention (intracorporeal dilatation and Al-Ghorab shunt).
- Corpus cavernosum blood gas analysis revealed severe acidosis and hypoxemia.
Findings:
- Erythropoietin injections and heparin administration during hemodialysis were identified as potential priapism triggers.
- The case highlights the complex interaction between erythropoietin, heparin, and the coagulation cascade in priapism development.
Implications:
- This case emphasizes the need for vigilance regarding priapism in hemodialysis patients.
- Further research is crucial to elucidate the specific mechanisms linking hemodialysis treatments to priapism.
- Understanding these mechanisms can lead to improved patient management and preventative strategies.
Related Concept Videos
01:27Dialysis
309
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
309
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
156
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
156
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176